CIAM
BGLC icon

Caitong International Asset Management’s BioNexus Gene Lab BGLC Stock Holding History

Caitong International Asset Management’s Portfolio BGLC Stock Details BGLC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2 Buy
+1
New +$2 ﹤0.01% 2818

Other funds holding BGLC

HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Caitong International Asset Management's BGLC Position: Q2 2026 in Review

Caitong International Asset Management opened a new position in BioNexus Gene Lab (BGLC) in Q2 2026: 1 share worth $2. The stake represents ﹤0.01% of the portfolio and ranks #2818 among its holdings.

3 funds tracked by Wall St. Rank hold BGLC as of Q2 2026.

  • Caitong International Asset Management held 1 share of BioNexus Gene Lab worth $2 as of Q2 2026.
  • BioNexus Gene Lab was a new Caitong International Asset Management position in Q2 2026.
  • BioNexus Gene Lab made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #2818 holding.
  • 3 funds tracked by Wall St. Rank held BioNexus Gene Lab as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.